AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$KROS

Newton Charles W. sold $6K of KROS

Newton Charles W. sold 551 shares of Keros Therapeutics, Inc. (KROS) at $10.30 on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Newton Charles W.
Published Aug 20, 2026, 8:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KROS
Neutral
high confidence
Mentioned
$KROS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KROSNeutralLow
01

Why it matters

The transaction is a routine liquidity event under a pre-arranged plan, offering little new insight.

02

Market read

Limited relevance; typical insider sell with minimal market effect.

03

What to watch

Potential upcoming corporate actions not disclosed.

Relevance 2/10Novelty 4/10Timing: filed today

Background

Form 4 filings disclose insider trades; investors monitor for material changes.

Company-level read

Ticker impact

$KROSNeutralHigh confidence
Context

Director Newton Charles W. sold 551 shares for $5,675.30 via a 10b5-1 plan.

Expected impact

No material impact expected.

Evidence & confidence

Sale size is small relative to total holdings and market cap; typical for planned liquidity.

Market effects

Sector

None; isolated insider transaction.

Regional

None; company-specific filing.

Global

None

Counterpoint

What could challenge this read

If insiders are reducing stakes, could signal concerns, but size is negligible.

Key entities

  • Company
    Keros Therapeutics, Inc.

    Biopharma listed on NASDAQ under KROS.

  • Insider
    Newton Charles W.

    Director of Keros Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KROS insider trading history →

Related articles

SEP 28
$KROSMedAI 8/10

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Keros Therapeutics, Inc. (KROS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD • Initial data expected in the first half of 2027 LEXINGTON, Mass., September 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: K

SEC EDGAR 8-K2 min